Zinc is an essential trace element important for various biological processes. Imbalance in Zn 2+ homeostasis is associated with immunological disorders such as inflammation, diabetes, asthma, rheumatoid arthritis and Alzheimer's disease (1,2). It is also associated with pancreatic (3), prostatic (4) and esophageal squamous cell carcinoma (5). The diverse roles of this ion in regulating cell signal transduction pathways and gene expression perhaps plays a part in the development of these diseases. Microarray analyses on rat intestine (6) and liver tissues (7, 8) , human leukocyte subsets and lymphoblastoid cell (9-13), human colon adenocarcinoma cells (14), esophageal squamous cell carcinoma (5) and normal prostate epithelial cells (15) identified group of genes affected by changes in Zn 2+ status. These include genes that regulate cell growth, metabolism, DNA repair, signal transduction, protein folding, energy production and genes that encode for heavy metal binding proteins, transporters, cytokines, cytokine receptors, adhesion molecules and T cells functions. These findings strongly support the regulatory roles of Zn 2+ in cell growth and proliferation.
Introduction
Zinc is an essential trace element important for various biological processes. Imbalance in Zn 2+ homeostasis is associated with immunological disorders such as inflammation, diabetes, asthma, rheumatoid arthritis and Alzheimer's disease (1, 2) . It is also associated with pancreatic (3), prostatic (4) and esophageal squamous cell carcinoma (5) . The diverse roles of this ion in regulating cell signal transduction pathways and gene expression perhaps plays a part in the development of these diseases. Microarray analyses on rat intestine (6) and liver tissues (7, 8) , human leukocyte subsets and lymphoblastoid cell (9) (10) (11) (12) (13) , human colon adenocarcinoma cells (14) , esophageal squamous cell carcinoma (5) and normal prostate epithelial cells (15) identified group of genes affected by changes in Zn 2+ status. These include genes that regulate cell growth, metabolism, DNA repair, signal transduction, protein folding, energy production and genes that encode for heavy metal binding proteins, transporters, cytokines, cytokine receptors, adhesion molecules and T cells functions. These findings strongly support the regulatory roles of Zn 2+ in cell growth and proliferation.
In a number of studies, Zn 2+ is also reported to play important roles in the development and progression of prostate cancer. Its uniquely high concentration in the prostate gland is essential for the normal function of prostate cells and spermatozoa (16) . Zn 2+ is found significantly lower in malignant prostate tissues in comparison to the normal tissues (17) . Zn 2+ regulates the signal transduction pathways that are implicated in prostate tumorigenesis (18, 19) and affects prostate cell growth and replication through various mechanisms (20) (21) (22) . Whether Zn 2+ regulates specific group of genes that are involved in prostate carcinogenesis or genes that increased malignant potentials in the cancerous prostate cells remained to be studied. In a recent study, we showed that high intracellular Zn 2+ affected LNCaP prostatic cancer cell growth by modulating the ERK/VHR/ZAP70-associated pathways (23) . The high intracellular Zn 2+ , however, has no influence on the prostate cancer cell senescence nor apoptosis (24) . In the present study, we simulated the effects ONCOLOGY REPORTS 23: 1501 -1516 , 2010 Comparative transcriptional study of the effects of high intracellular zinc on prostate carcinoma cells of progressive long-term intracellular Zn 2+ accumulation by prolonged culturing of the LNCaP cells in growth medium supplemented with supraphysiologic concentration of Zn 2+ and examined the effects on the prostate cancer cell growth and proliferation and on the Zn 2+ -responsive genes.
Materials and methods
Cell culture and treatments. Human prostate cancer cells, LNCaP.FGC, were purchased from American Type Culture Collection (Rockville, USA). Human normal prostate epithelial cells, PNT2 were obtained as gift from Dr R. Rosli, Universiti Putra Malaysia. The cells were cultured in RPMI-1640 (Flowlab, Australia) supplemented with 10% FBS (Biowhittaker, USA), nonessential amino acid (1 mM), L-glutamine (2 mM) and 10 mM HEPES at 37˚C in humidified atmosphere of 5% CO 2 . LNCaP cells were propagated in growth medium containing 1 or 10 μg/ml of ZnSO 4 for 5 passages in 5 weeks and subsequently analyzed as shown in the schematic timeline ( Fig. 1 ). Control cell cultures were supplemented with only the Zn 2+ diluent and propagated in parallel with the Zn 2+ -supplemented cells. Cell proliferation rate and intracellular Zn 2+ concentrations were measured as previously described (23) . In separate experiments, shortterm Zn Soft agar colony formation assay. LNCaP prostate cancer cells were treated with Zn 2+ for 5 weeks. Cells were then assayed for anchorage-independent growth determined by their ability to form tumor colonies using soft agar colony formation assay. Single cell suspension was obtained by repeatedly passing cells through a 26Gxó' needle (Terumo, Japan). Five thousand cells were then resuspended in growth medium containing 0.3% agar (DNA grade agarose, Promega, USA). The cell suspension was layered on top of a base layer consisting of 0.5% agar prepared in growth medium in 60-mm plastic petri dishes (Falcon, USA). The cultures were incubated for 3 weeks at 37˚C in a humidified chamber supplied with 5% CO 2 in air. The growth medium was replenished every 3 days and cell colonies were counted after 3 weeks of incubation. Only colonies >0.5 mm were counted.
RNA extraction and target RNA preparation. Total cellular RNA of the Zn 2+ -treated cells at the end of passage 5 (week 5) from representative experiments (n=3) was extracted from cells using TRI reagent ® (Molecular Research Center, USA) and purified using RNeasy ® Mini RNA Isolation Kit (Qiagen, Germany). Purified RNA integrity was checked by separating the RNA by electrophoresis in formaldehyde agarose gel. Complementary RNA (cRNA) amplification was then performed using Illumina ® RNA Amplification Kit (Ambion, USA) according to the manufacturer's instructions. Approximately 100 ng of total RNA was reverse transcribed using the T7 oligo (dT) primer to prime cDNA synthesis. Following the second strand cDNA synthesis and column purification, in vitro transcription (IVT) was performed using biotinylated UTP to synthesize biotinylated cRNA. The cRNAs were column purified and used for hybridization. Illumina Human Ref Seq-8 Sentrix Bead Chip Arrays consisting of ~24,000 transcript probes (n=2 for control and n=3 for Zn 2+ -supplemented cells) were hybridized with 850 ng biotinylated cRNA at 55˚C for 16 h. The arrays were washed, stained with strepavidin-Cy3 conjugate (2 μg/ chip; GE Biosciences, USA) and scanned following the instruction for the Illumina BeadStation 500x (Illumina, USA).
Microarray data analysis. Microarray data were analyzed using the Genespring GX 7.3 (Agilent Technologies Inc., USA). Signal intensity values <0.01 were adjusted to the minimal intensity values of 0.01. Data were normalized to 50th percentile per chip and then to the median value per gene to compensate for experimental biases introduced by individual chip and differences in the detection efficiency between different spots. The raw data intensity values were then log transformed (log 2 ) to increase detection efficiency in discriminating differences between groups whose withingroup variances are very different. Differential gene expression analysis was performed on Volcano plot using a cut-off fold change of 1.5 and parametric test with all available error estimates with Benjamini and Hochberg False Discovery Rate corrections (FDR of 0.05) (25) . Hierarchical Clustering was performed on the normalized data using Genespring GX 7.3 (Agilent Technologies Inc.). Standard correlation was used as the dissimilarity estimates and average linkage method was used as the clustering algorithm. In the average linkage method, the distance between two clusters was calculated as the arithmetic mean of the distance between all possible pairs from the two clusters. Genes responsive to high intracellular Zn 2+ were clustered based on biological process categories of the Gene Ontology Consortium (http:// www.geneontology.org) using a web-based annotation program called NMC Annotation Tool (26) . for 5 weeks were isolated. RNAs were isolated using the TRI Reagent (Molecular Research Center) following the manufacturer's protocol. The RNA was treated with DNase and then 2 μg of it was reverse-transcribed using SuperScript™ II Reverse Transcriptase (Invitrogen, USA). RTqPCR was performed using the SYBR-Green dye (Qiagen, UK) method on DNA Engine Opticon II (Bio-Rad, USA) with oligonucleotide primers shown in Table I . The primers were designed using Beacon Designer™ software (Premier Biosoft International, USA). Melt curve analysis was performed after each amplification followed by gel electrophoresis and DNA sequencing. Standard curves for internal standard (18S rRNA) and target genes were generated by linear regression using threshold cycle values, C t versus log (standard dilutions). Amplification efficiency of the internal standard and target gene was determined in each run using the following equation: efficiency = 10 (-1/slope) -1. The initial copy number of the target gene in each sample (control untreated and Zn 2+ -treated sample) was extrapolated from the standard curves. The initial target gene copy number was then normalized to the initial copy number of 18S rRNA in the respective sample. Fold-change in gene expression was calculated by dividing the normalized copy number of the target gene in the Zn 2+ -treated sample with the normalized copy number of the target gene in the control untreated sample (27) . RT-qPCR for all genes was performed in triplicates in at least three separate amplifications from 2 separate experiments. Data are presented as mRNA copies of target genes per 10 8 copies of 18S rRNA.
Quantitative real-time reverse transcriptase PCR (RTqPCR
Statistical analysis. Statistical analyses were performed using GraphPad Prism Version 4.03 (GraphPad Software Inc., USA). Data were expressed as the mean ± standard error of mean (SEM). Statistical differences were analyzed using t-test. A p-value <0.05 was considered as significantly different.
Results

The effects of a high intracellular Zn 2+ level on LNCaP cells proliferation. High intracellular Zn
2+ was restored to the LNCaP prostate cancer cells as previously described (23) . The LNCaP prostate cancer cell proliferation rate after the long-term culture in Zn 2+ was examined by stimulating the cells to proliferate at week six post-initiation of the Zn 2+ treatment (Fig. 1) . The proliferation rate of cells cultured in 1 μg/ml Zn 2+ was comparable to that of the non Zn 2+ -treated cells ( Fig. 2A) . The proliferation rates for cells treated with supraphysiologic Zn 2+ (10 μg/ml), however, were significantly lowered at 42.2±7.4%, 76.7±2.0% and 35.8±5.6% in comparison to the non Zn 2+ -treated cells on days 3, 6 and 9, respectively ( Fig. 2A) . No significant growth differences were observed on day 12 (~7 weeks post-initiation of the treatment) between the supraphysiologic Zn 2+ -supplemented cells (13.2±1.7%) and cells supplemented with only physiologic Zn 2+ or without additional Zn 2+ . In addition, the proliferation rate of cells supplemented with supraphysiologic Zn 2+ was also significantly lower on days 3 and 6 (48.1±6.6% and 44.9±4.8%, respectively) when compared to that of the normal PNT2 prostate cells ( Fig. 2A) , suggesting that the ONCOLOGY REPORTS 23: 1501 -1516 , 2010 Table I. Quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) amplification primer pairs used in the study. 2+ on the LNCaP cell anchorage-independent growth after 5 weeks of treatment were determined using the soft agar colony formation assay. Data from representative experiments (n=6) showed that the transformation frequency of the control non Zn 2+ -supplemented LNCaP cells was 0.92±0.12%. The transformation frequencies for LNCaP cells supplemented with physiologic (1 μg/ml) and supraphysiologic (10 μg/ml) Zn 2+ concentrations for 5 weeks were significantly reduced to 0.38±0.12% (p<0.05, t-test) and 0.06±0.02% (p<0.0001, t-test), respectively (Fig. 3) . These findings suggested that the restoration of high intracellular Zn 2+ transiently restricted LNCaP prostate cancer cell anchorage-independent growth after 5 weeks of treatment (Fig. 3) .
The effects of a high intracellular Zn
2+ level on LNCaP prostate cancer cell gene expression. The gene expression profile of LNCaP prostate cancer cells treated with supraphysiologic Zn 2+ (10 μg/ml) for 5 weeks was examined using Illumina Human RefSeq-8 Sentrix Bead Chip 24,000 Gene Array (Illumina, USA). Data obtained were transformed and normalized to 50th percentile per chip and the median value per gene. Using a threshold factor of 1.5-fold change in signal intensity and Benjamini and Hochberg correction (FDR of 0.05), 161 zinc-upregulated genes were obtained without significantly downregulated genes (Fig. 4 , Table II ). Table II . Continued. 
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GenBank Fold-Corrected No. accession no. The mRNA expressions of selected genes from the list of genes that were highly responsive to the Zn 2+ treatment were further quantified using quantitative real-time RT-PCR (RTqPCR). Of the 9 selected genes, 4 genes showed comparable mRNA expression fold changes to those found in microarray analysis while the other 5 genes had even higher fold changes when compared to those identified from the microarray analysis (Fig. 5) . At least 12 different functional gene groups were obtained from the 161 genes found responsive to high intracellular Zn 2+ when clustered based on biological process categories of the Gene Ontology Consortium (Fig. 6 ) using the web-based annotation program NMC Annotation Tool (26) . These groups consist of genes that encode for proteins involved in translation (10.6%), cell proliferation/cell death/ cell cycle regulation (7.6%), signal transduction (8.1%), metabolism (8.6%), transcription (8.6%), ion/protein transport ONCOLOGY REPORTS 23: 1501 -1516 , 2010 1509 Table II . Continued.
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(7.6%), RNA processing (6.1%), protein folding/modification (5.1%), cell adhesion/cell motility (4.0%), DNA repair/DNA replication (4.5%) and multicellular organismal development (4.0%). Several genes that are involved in various biological processes such as immune responses, secretion, excretion, endocytosis and sensory perception of sound were grouped under 'other' category (7.1%) and a larger fraction of the genes (18.2%), comprised of hypothetical genes or genes with unknown function were grouped under 'uncharacterized' category.
The microarray analysis revealed several genes associated with cell growth inhibition, DNA damage/repair, oxidative stress and decreased tumor colony formation abilities were affected by the high intracellular Zn 2+ treatment of the LNCaP cells. These included (36) and SHC-1 (37) that negatively regulate cell growth. Whereas, RAD51L1, MSH3 (38) , ATMIN (39) and NONO (40) were upregulated usually in response to DNA damage/repair and ME1 (41), was upregulated in response to oxidative stress. MT-1F (42) and WIG1/ZMAT3 (43) found upregulated were usually associated to a decrease in tumor colony formation efficiency similar to results obtained when the LNCaP cells were treated with supraphysiologic Zn 2+ at 5 weeks posttreatment (Table III) . Approximately 16.1% of the upregulated genes, however, were genes commonly found overexpressed in malignant tissues/cells and those that promote cell proliferation, adhesion and migration (Table III) . These included CD164 (44) (55) and FBL (56) . Some of these genes were also previously reported to be overexpressed in prostate cancer tissues (44) (45) (46) (47) 49, 50, 53, (57) (58) (59) .
The effects of short-term Zn 2+ treatments on LNCaP and PNT2 cell gene expression. Five genes identified as highly responsive (>1.7-fold, with exception of E2F3 gene at 1.5 fold) to supraphysiologic Zn 2+ concentration from the 161 Zn 2+ -responsive genes were selected for further examination in LNCaP prostate cancer cells and PNT2 prostate normal cells. PNT2 and LNCaP cells were treated with 10 μg/ml Zn 2+ and the mRNA expression levels at intervals up to 72 h were quantified by quantitative reverse transcriptase PCR (RT-qPCR). Results obtained for LNCaP cells treated with Zn 2+ (10 μg/ml) for 5 weeks were included for comparison. Comparative transcription studies of CD164, E2F3, FBL, STEAP1 and TACSTD1 genes showed a timedependent increase in mRNA expression levels of these genes in the Zn 2+ -treated LNCaP cells beginning at 16 h post-treatment (Fig. 7) . The mRNA expression levels of these genes in the non Zn 2+ -treated cells harvested at 72 h and cells treated with 100 μM N, N, N', N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to chelate Zn 2+ remained lower than the Zn 2+ -treated cells. At 16 h post-treatment, the mRNA levels of CD164, FBL and TACSTD1 genes of the Zn 2+ -treated LNCaP cells were 2.2±0.3-fold, 4.5±0.7-fold and 2.7±0.6-fold, respectively, higher than the non Zn 2+ -treated LNCaP cells (Fig. 7A, C and E; p<0.01, t-test) . The mid logarithmic increase in the mRNA expression for CD164, FBL and TACSTD1 genes were observed at ~18 h post-treatment (Fig. 7) . At 72 h post-treatment, the mRNA expression of CD164, FBL and TACSTD1 had increased by 3.5±0.4-fold (p<0.01, t-test), 5.6±0.6-fold (p<0.001, t-test) and 5.1±0.5-fold (p<0.001, t-test) when compared to the non Zn 2+ -treated LNCaP cells (Table IV) . On the other hand, the mid logarithmic increase in the mRNA expression of E2F3 and STEAP1 genes was at ~36 h post-treatment suggesting a delay in response to Zn 2+ by these genes. At 48 h posttreatment, the mRNA expression levels of E2F3 and STEAP1 of the Zn 2+ -treated LNCaP cells were 3.03±0.7-fold (p=0.046, t-test) and 2.0±0.3-fold (p<0.001, t-test), respectively, higher than the non Zn 2+ -treated LNCaP cells and remained almost unchanged at 72 h post-treatment (3.3±0.3-fold and 3.1±0.3-fold, respectively) ( Fig. 7B and D Table III . Selected LNCaP cell genes that responded to the high intracellular Zn 2+ treatment. 
a Genes selected for short-term Zn 2+ -treatment and RT-qPCR analysis in LNCaP and PNT2 cells.
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.9±0.9-fold, respectively, in comparison to the non Zn 2+ -treated LNCaP (Fig. 7) .
The mRNA expression of CD164, FBL and TACSTD1 in the Zn 2+ -treated PNT2 increased only beginning at 48 h posttreatment and this was in contrast to 16 h in the LNCaP cells (Fig. 7) . The mRNA levels of CD164, FBL and TACSTD1 increased by 3.3±0.1-fold, 13.5±1.9-fold and 4.4±0.5-fold higher than the non Zn 2+ -treated PNT2 cells (Fig. 7A , C and E). At 72 h post-treatment, the mRNA levels of CD164, FBL and TACSTD1 increased by 2.2±0.2-fold, 7.6±1.0-fold and 3.2±0.5-fold higher than theZn 2+ -treated PNT2 cells (Fig. 7A, C and E) . The mRNA levels of the housekeeping gene, ß-actin, also increased by 2.8±0.2-fold and 1.3±0.2-fold at 48 and 72 h post-treatment, respectively, in the non Zn 2+ -treated PNT2 cells (Fig. 7F) . The levels of ß-actin mRNA were otherwise unchanged at other time points in both the Zn 2+ -treated LNCaP and PNT2 cells. The slight increase in ß-actin mRNA was not unexpected as 18S rRNA was used for normalization of the data in the study and it has its shortcomings (60, 61) .
The RT-qPCR results from the study showed that the cell growth promoting genes CD164, FBL and TACSTD1 were responsive to the high intracellular Zn 2+ treatment in both PNT2 prostate normal and LNCaP prostate cancer cells (Table IV) (23) . Results from our microarray study, further suggest that the increase in intracellular Zn 2+ level is also reflected by the increase in mRNA expressions of MT-1G and MT-1F which are radical scavengers that chelate and sequester excessive metal ions (11) . The Zn 2+ treatment, however, did not result in significant changes in the mRNA expression of Zn 2+ transporters, hZIP-1 and ZnT1, which is in agreement with an earlier report (62) suggesting that regulation of these transporter gene expressions is not directly regulated by the intracellular Zn 2+ level. It is shown in the present study that cells treated with supraphysiologic Zn 2+ exhibited reduced cell proliferation rate at the exponential point only. The inhibition is transient as the cell proliferation rate and anchorage-independent growth later attained the levels comparable to that of untreated cells. These results are incongruent with an earlier study that shows that there is no induction of senescence or apoptosis in the Zn 2+ -treated cell cultures (24) . It also suggests that somehow the initial inhibitory effects of Zn 2+ on LNCaP cell proliferation is reversed in the continuous presence of high intracellular Zn 2+ hence, allowing the cancer cells to attain its normal cancerous cell growth rate.
Contradicting findings with regards to the effects of Zn 2+ on prostate cancer cell growth and invasion have been reported (18, 22, (63) (64) (65) . While there are suggestions that dietary zinc supplementation protects against oxidative damage, reduces cancer risk (66) and is beneficial against prostate tumorigenesis (67) , recent reports showed that advanced prostate cancer is associated with high intake of zinc (68) (69) (70) . Higher intake of dietary zinc could also potentiate the development of BPH and progression towards cancer (71, 72) . These reports raised concern of the potential detrimental outcomes of long-term use of high zinc-supplements in men even though the reason behind the increased in prostate cancer risk is unclear. To date, no satisfactory mechanisms have been forwarded to explain these seemingly contradicting roles of zinc in prostate cancer tumorigenesis. In an earlier study, it was shown that Zn 2+ deficiency in normal prostate epithelial cells resulted in altered expression of genes associated with cell cycle, DNA damage/repair and gene transcription, suggesting that Zn 2+ has a protective role in DNA damage and protection against cancer development (15) . Results from the present study, however, showed that the LNCaP cells retained its cancerous proliferative rate and properties even though the expression of DNA damage/ repair, oxidative stress and apoptosis-related genes are upregulated in the presence of supraphysiologic zinc. This implies that there are potentially other zinc-associated mechanisms involved in the survival of the prostate cancer cells. Results presented here also showed that prostate cancer cell proliferation in the presence of supraphysiologic concentration of Zn 2+ is accompanied by high expression of FASN, FAD, TACSTD1, FBL, ADRM1, E2F3, CD164 and STEAP1 genes. Earlier studies have shown that CD164 (44) and TACSTD1 (49) are overexpressed in prostate cancer tissues where Zn 2+ level is known to be low. While the expressions of these genes are constitutively high in prostatic cancer cells, restoration of high intracellular Zn 2+ did not reduce their expressions, on the contrary it superinduced the expressions of these genes suggesting that the regulation of these genes by Zn 2+ is lost irreversibly in prostatic cancer cells. These genes are known to promote prostate cancer cell proliferation, aggressiveness and for some of these genes, the expression is associated with poor survival outcomes of cancer patients. We also found that CD164, FBL and TACSTD1 were regulated by Zn 2+ in normal prostate PNT2 cells and these suggest that while Zn 2+ initially suppresses cell growth, perhaps by repressing the expressions of selected growth promoting genes, it could also alternatively facilitate the survival of prostate cancer cell through mechanisms involving these very genes, possibly through an autostimulating pathways that superinduce the expression of the genes. Hence, prolonged high Zn 2+ -treatment could actually induce aggressive behavior of the prostate cancer cells. This suggestion offers a possible explanation to the development of prostate cancer. Perhaps during the very early stages of prostate cancer, the presence of relatively high level of zinc regulates the expression of these genes and only when significant subsequent changes in Zn 2+ homeostasis occur that it trigger uncontrolled prostate cell growth leading to cancer.
How Zn 2+ affects CD164, FBL and TACSTD1 is still unclear. CD164 and TACSTD1 (Ep-CAM) are cell adhesion molecules important for cell migration, proliferation, and differentiation (73, 74) . CD164 is implicated in prostate cancer metastasis by promoting the immobilization of cancer cells to bone marrow through the CXCL12/CXCR4 pathway (44) . Whereas, fibrillarin (FBL), another gene found constitutively high in LNCaP cells and is superinduced by high intracellular Zn 2+ is a nucleolar U3 ribonucleoprotein particle that is important for pre-rRNA processing during ribosomal biogenesis and maintains nuclear shape and cellular growth (75) . FBL is also found upregulated in human cervical squamous cell carcinoma (56) and hepatocellular carcinoma (76) . STEAP1, on the other hand is highly expressed in multiple cancer cells including prostate, bladder, colon, ovarian and Ewing sarcoma (77) and we showed here that its expression in LNCaP cells is ~56-fold higher than in PNT2 prostate normal cells, yet it is not responsive to Zn 2+ in comparison to other genes studied. STEAP1 is a transmembrane protein with a potential role in the reduction of copper and iron (78) . It is likely therefore, that Zn 2+ which does not participate in redox reaction (79) may not have an effect on STEAP1 expression. The mechanisms of how other genes except STEAP1 are superinduced following longterm high intracellular Zn 2+ treatment are still unknown. We had previously shown that under similar conditions the Zn 2+ -regulation of LNCaP cell growth could be mediated through the ERK/VHR/ZAP-70 pathway (23) . The finding in the present study that genes such as C1QBP1 (31), SHC1 (80), AHR (81), ARF4 (82), RPS6KB2 (83) and KTN1 (84) are upregulated following Zn 2+ treatment supported this suggestion, as these genes are known to be regulated through the ERK signaling pathway highlighting the potential importance of this pathway in prostate cancer biogenesis.
Taken together, findings from the present study offer possible explanations to the contradicting reports on the influence of zinc on prostate cancer development. Zn 2+ may have suppressive effects on prostate cancer cell growth initially but its presence at high level under transformed condition may results in deleterious consequences. Zn 2+ -based therapy for prostate cancer, hence, may potentially contribute to undesirable outcomes.
